A subtle punctuated addendum in PR to cue the shareholders and markets as to their plans in regard to this blockbuster and other B.P. challengers from Berkeley Bio.
Quote: "Alzatrex™ will be available soon in dispensaries and delivery services across California, to start. "
"to start"
###
SK3 Group's Berkeley Bio Organic Research Laboratories Has Developed Cutting Edge Nutritional Supplement, Alzatrex™, Targeted to Assist Those with Memory Deficits and to Reduce Brain Fog from MMJ Use
Mar 11, 2014
LOS ANGELES, CA--(Marketwired - Mar 11, 2014) - SK3 Group's (OTC Pink: SKTO) (PINKSHEETS: SKTO) Berkeley Bio Organic Research Laboratories has developed "Alzatrex"™, an herbal supplement that may be taken orally that combines medical cannabis with a proprietary formula of herbal COX-2 inhibitors. Research has shown that delta9-THC, the main active ingredient in medical marijuana, decreases beta-amyloid plaques and neurodegeneration in Alzheimer's disease, and that it is reduced further by the addition of a COX-2 inhibitor. A COX-2 inhibitor is a form of NSAID that is used to reduce pain.
The combination of a COX-2 inhibitor with medical cannabis also prevents marijuana-induced memory problems and "brain fog" or "haze" that is common. Further, as stated in the journal Cell, "These results suggest that the applicability of medical marijuana would be broadened by concurrent inhibition of COX-2."
See Cell, Chen et al.: "delta9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling" at http://www.cell.com/retrieve/pii/S0092867413013603?cc=y .
Although the Centers for Disease Control and Prevention has estimated that 5 million Americans are living with Alzheimer's disease, and that 83,000 die from the condition every year, a new study has found that nearly half a million elderly Americans likely died from Alzheimer's disease in 2010, which is almost 6 times higher than previous estimates according to a new study released Wednesday. This moves Alzheimer's from the sixth-leading cause of death in the U.S. to the third-leading killer, right behind heart disease and cancer.
See Neurology, "Contribution of Alzheimer disease to mortality in the United States" at http://www.neurology.org/content/early/2014/0...4bd0bc4e28 .
Furthermore, COX inhibitors have been shown to reduce the occurrence of cancers and pre-cancerous growths.
Artemus Mayor, President of SK3 Group, Inc., said, "We see this as an opportunity to help the many people suffering with Alzheimer's disease. Our new Alzatrex™ product will not only help those with Alzheimer's and dementia, but it will also help medical marijuana patients reduce the side-effects of cannabis, mainly the 'brain fog' that is so common. We are using technology to improve the lives of patients."
Alzatrex™ will be available soon in dispensaries and delivery services across California, to start.
About SKTO
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
FDA Statement
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SK3 Group
Investor Relations
investors@medicalgreens.com
Copyright © 2014 Marketwired. All Rights Reserved
Quote: "Alzatrex™ will be available soon in dispensaries and delivery services across California, to start. "
"to start"
###
SK3 Group's Berkeley Bio Organic Research Laboratories Has Developed Cutting Edge Nutritional Supplement, Alzatrex™, Targeted to Assist Those with Memory Deficits and to Reduce Brain Fog from MMJ Use
Mar 11, 2014
LOS ANGELES, CA--(Marketwired - Mar 11, 2014) - SK3 Group's (OTC Pink: SKTO) (PINKSHEETS: SKTO) Berkeley Bio Organic Research Laboratories has developed "Alzatrex"™, an herbal supplement that may be taken orally that combines medical cannabis with a proprietary formula of herbal COX-2 inhibitors. Research has shown that delta9-THC, the main active ingredient in medical marijuana, decreases beta-amyloid plaques and neurodegeneration in Alzheimer's disease, and that it is reduced further by the addition of a COX-2 inhibitor. A COX-2 inhibitor is a form of NSAID that is used to reduce pain.
The combination of a COX-2 inhibitor with medical cannabis also prevents marijuana-induced memory problems and "brain fog" or "haze" that is common. Further, as stated in the journal Cell, "These results suggest that the applicability of medical marijuana would be broadened by concurrent inhibition of COX-2."
See Cell, Chen et al.: "delta9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling" at http://www.cell.com/retrieve/pii/S0092867413013603?cc=y .
Although the Centers for Disease Control and Prevention has estimated that 5 million Americans are living with Alzheimer's disease, and that 83,000 die from the condition every year, a new study has found that nearly half a million elderly Americans likely died from Alzheimer's disease in 2010, which is almost 6 times higher than previous estimates according to a new study released Wednesday. This moves Alzheimer's from the sixth-leading cause of death in the U.S. to the third-leading killer, right behind heart disease and cancer.
See Neurology, "Contribution of Alzheimer disease to mortality in the United States" at http://www.neurology.org/content/early/2014/0...4bd0bc4e28 .
Furthermore, COX inhibitors have been shown to reduce the occurrence of cancers and pre-cancerous growths.
Artemus Mayor, President of SK3 Group, Inc., said, "We see this as an opportunity to help the many people suffering with Alzheimer's disease. Our new Alzatrex™ product will not only help those with Alzheimer's and dementia, but it will also help medical marijuana patients reduce the side-effects of cannabis, mainly the 'brain fog' that is so common. We are using technology to improve the lives of patients."
Alzatrex™ will be available soon in dispensaries and delivery services across California, to start.
About SKTO
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
FDA Statement
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SK3 Group
Investor Relations
investors@medicalgreens.com
Copyright © 2014 Marketwired. All Rights Reserved
